tradingkey.logo

Transmedics Group Inc

TMDX

92.430USD

+2.240+2.48%
Close 04/29, 16:00ETQuotes delayed by 15 min
3.11BMarket Cap
87.62P/E TTM

Transmedics Group Inc

92.430

+2.240+2.48%
More Details of Transmedics Group Inc Company
TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside the human body. It also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ procurement, OCS perfusion management and transplant logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation and other coordination activities. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.
Company Info
Company codeTMDX
Company nameTransmedics Group Inc
IPO dateMay 02, 2019
Founded at2018
CEODr. Waleed H. Hassanein, M.D.
Number of employees728
Security typeOrdinary Share
Fiscal year-endMay 02
Address200 Minuteman Road
CityANDOVER
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code01810
Phone19785520900
Websitehttps://www.transmedics.com/
Company codeTMDX
IPO dateMay 02, 2019
Founded at2018
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Waleed H. Hassanein, M.D.
Dr. Waleed H. Hassanein, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
481.61K
-8.98%
Mr. James R. Tobin
Mr. James R. Tobin
Independent Chairman of the Board
Independent Chairman of the Board
175.07K
-21.19%
Dr. David Weill, M.D.
Dr. David Weill, M.D.
Independent Director
Independent Director
10.73K
--
Mr. Nicholas (Nick) Corcoran
Mr. Nicholas (Nick) Corcoran
Senior Vice President - Supply Chain and Operations
Senior Vice President - Supply Chain and Operations
7.04K
-44.49%
Ms. Merilee Raines, CPA
Ms. Merilee Raines, CPA
Independent Director
Independent Director
1.93K
--
Ms. Stephanie Lovell
Ms. Stephanie Lovell
Independent Director
Independent Director
1.93K
--
Mr. Thomas James Gunderson
Mr. Thomas James Gunderson
Independent Director
Independent Director
1.93K
--
Mr. Anil Ranganath
Mr. Anil Ranganath
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
1.87K
-87.03%
Mr. Gerardo Hernandez
Mr. Gerardo Hernandez
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
331.00
-97.93%
Mr. Edwin M. Kania, Jr.
Mr. Edwin M. Kania, Jr.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Waleed H. Hassanein, M.D.
Dr. Waleed H. Hassanein, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
481.61K
-8.98%
Mr. James R. Tobin
Mr. James R. Tobin
Independent Chairman of the Board
Independent Chairman of the Board
175.07K
-21.19%
Dr. David Weill, M.D.
Dr. David Weill, M.D.
Independent Director
Independent Director
10.73K
--
Mr. Nicholas (Nick) Corcoran
Mr. Nicholas (Nick) Corcoran
Senior Vice President - Supply Chain and Operations
Senior Vice President - Supply Chain and Operations
7.04K
-44.49%
Ms. Merilee Raines, CPA
Ms. Merilee Raines, CPA
Independent Director
Independent Director
1.93K
--
Ms. Stephanie Lovell
Ms. Stephanie Lovell
Independent Director
Independent Director
1.93K
--
Revenue Breakdown
Currency: USDUpdate time: Sun, Apr 6
Currency: USDUpdate time: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
OCS Liver net revenue
309.62M
70.83%
OCS Heart net revenue
109.86M
25.13%
OCS Lung net revenue
17.68M
4.04%
By RegionUSD
Name
Revenue
Proportion
United States
421.88M
96.50%
All other countries
15.28M
3.50%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
OCS Liver net revenue
309.62M
70.83%
OCS Heart net revenue
109.86M
25.13%
OCS Lung net revenue
17.68M
4.04%
Shareholder
Update time: Sun, Feb 23
Update time: Sun, Feb 23
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
BlackRock Institutional Trust Company, N.A.
14.45%
Fidelity Management & Research Company LLC
11.68%
The Vanguard Group, Inc.
10.73%
State Street Global Advisors (US)
4.02%
Macquarie Investment Management
2.93%
Other
56.19%
Shareholder Statistics
Shareholder
Proportion
BlackRock Institutional Trust Company, N.A.
14.45%
Fidelity Management & Research Company LLC
11.68%
The Vanguard Group, Inc.
10.73%
State Street Global Advisors (US)
4.02%
Macquarie Investment Management
2.93%
Other
56.19%
Type
Shareholder
Proportion
Investment Advisor
60.18%
Investment Advisor/Hedge Fund
38.06%
Hedge Fund
7.96%
Research Firm
3.62%
Individual Investor
2.99%
Bank and Trust
2.79%
Pension Fund
1.52%
Sovereign Wealth Fund
1.08%
Family Office
0.09%
Institutional Shareholding
Update time: Wed, Mar 5
Update time: Wed, Mar 5
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
722
40.40M
120.00%
-704.37K
2024Q4
728
40.09M
119.11%
-642.74K
2024Q3
673
39.30M
117.10%
+1.37M
2024Q2
615
36.53M
110.85%
-3.27M
2024Q1
544
37.44M
113.97%
-4.28M
2023Q4
512
38.18M
116.94%
-3.46M
2023Q3
482
38.42M
117.77%
-240.92K
2023Q2
462
35.43M
108.88%
-81.81K
2023Q1
431
32.52M
99.99%
-2.56M
2022Q4
396
31.20M
98.07%
-3.79M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
4.89M
14.52%
+7.50K
+0.15%
Dec 31, 2024
Fidelity Management & Research Company LLC
3.95M
11.74%
+1.99M
+101.32%
Dec 31, 2024
The Vanguard Group, Inc.
3.63M
10.78%
+40.48K
+1.13%
Dec 31, 2024
State Street Global Advisors (US)
1.36M
4.04%
+88.13K
+6.92%
Dec 31, 2024
Macquarie Investment Management
992.50K
2.95%
+96.39K
+10.76%
Dec 31, 2024
UBS Asset Management Switzerland AG
973.96K
2.89%
+45.00K
+4.84%
Feb 28, 2025
Braidwell LP
922.10K
2.74%
+922.10K
--
Dec 31, 2024
UBS Asset Management (Switzerland)
866.16K
2.57%
+839.95K
+3.21K%
Dec 31, 2024
Fidelity International
855.36K
2.54%
+259.51K
+43.55%
Dec 31, 2024
Mackenzie Investments
828.15K
2.46%
+349.40K
+72.98%
Dec 31, 2024
View more
Related ETFs
Update time: Sun, Apr 6
Update time: Sun, Apr 6
Name
Proportion
Clough Select Equity ETF
3.03%
Clough Hedged Equity ETF
2.66%
SPDR S&P Health Care Equipment ETF
1.53%
Invesco S&P SmallCap Health Care ETF
1.53%
First Trust Nasdaq Lux Digi Health Solutions ETF
1.02%
Invesco S&P SmallCap 600 Pure Growth ETF
0.85%
BNY Mellon Innovators ETF
0.62%
Fidelity Sustainable US Equity ETF
0.57%
WisdomTree US SmallCap Quality Growth Fund
0.43%
SPDR S&P 600 Small Cap Growth ETF
0.33%
View more
Clough Select Equity ETF
Proportion3.03%
Clough Hedged Equity ETF
Proportion2.66%
SPDR S&P Health Care Equipment ETF
Proportion1.53%
Invesco S&P SmallCap Health Care ETF
Proportion1.53%
First Trust Nasdaq Lux Digi Health Solutions ETF
Proportion1.02%
Invesco S&P SmallCap 600 Pure Growth ETF
Proportion0.85%
BNY Mellon Innovators ETF
Proportion0.62%
Fidelity Sustainable US Equity ETF
Proportion0.57%
WisdomTree US SmallCap Quality Growth Fund
Proportion0.43%
SPDR S&P 600 Small Cap Growth ETF
Proportion0.33%
Dividend
A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data